The future of Cross-Linking

CXL at the Slit Lamp: the C-Eye Device
KERATOCONUS

- Treatment is Costly
- Needs an Operating Theatre
- Limited access in developing countries
INFECTIOUS KERATITIS

- AMR (antimicrobial resistance), global challenge by 2050
- High costs of treatment
AMR, a global problem

How does AMR compare?
Major causes of death (annual figures)

- Tetanus: 60,000
- Cholera: 100,000 - 120,000
- Measles: 130,000
- AMR in 2050: 10,000,000

- Road traffic accidents: 1,200,000
- Diarrhoeal disease: 1,400,000
- Diabetes: 1,500,000
- Cancer: 8,200,000

Source: The Review on Antimicrobial Resistance
Infectious keratitis - “Silent epidemic” (WHO)

- Antibiotic resistance
- Mixed infections
- High costs
- 6-8 Million new cases / year
- 205’000 ophthalmologists

Developed countries

Developing countries
SOLUTION

- CXL at the Slit Lamp
HOW DOES IT WORK?
Multiple Intensities

- 3 mW/cm²
- 9
- 18
- 30

Real-Time Fluorescence Measurement

Optimized Irradiation Profile
- More intensity in the corneal periphery, to compensate for thickness increase.

Sterile Cap
- Sterile interface between device and corneal surface.
MULTIPLE INTENSITIES

- 3
- 9
- 18
- 30
- mW/cm²
REAL-TIME FLUORESCENCE MEASUREMENT
OPTIMIZED IRRADIATION PROFILE

- More intensity in the corneal periphery, to compensate for thickness increase.
STERILE CAP

- Sterile interface between device and corneal surface
EMAGine AG

- Swiss Company
- Spin-off from University of Geneva
- Based on extensive laboratory and clinical research

- Team members: more than 50 peer-reviewed scientific publications on Cross-Linking

- Our motto: “Science First, Marketing Second”
• Swiss Company
• Spin-off from University of Geneva
• Based on extensive laboratory and clinical research
Team members: more than 50 peer-reviewed scientific publications on Cross-Linking
Our motto:

“Science First, Marketing Second”
The future of Cross-Linking

**CXL at the Slit Lamp: the C-Eye Device**

**EMAGine AG**

- **KERATOCONUS**
  - Treatment is costly
  - Needs an Operating Theatre
  - Limited access in developing countries

- **INFECTIONOUS KERATITIS**
  - AMR (antimicrobial resistance), global challenge by 2050
  - High costs of treatment

- **SOLUTION**
  - CXL at the Slit Lamp

- **HOW DOES IT WORK?**